# 12 Pharmacy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/12-pharmacy

- Industry: Healthcare
- Headquarters: Tokyo, Japan
- Website: https://12pharmacy.co.jp
- Latest round: Series A (Apr 20, 2026)
- Investors on record: 6

## About

Based in Japan, 12 Pharmacy specializes in veterinary pharmaceuticals, delivering essential healthcare products and services for animals to enhance their well-being.Founded in 2023, 12 Pharmacy operates out of Tokyo, Japan, focusing on veterinary pharmaceuticals. In April 2026, 12 Pharmacy raised an undisclosed amount of series A funding from ARKRAY & PARTNERS Pte. Ltd., Beta Venture Capital, and FFG Venture Business Partners. 

12 Pharmacy specializes in a diverse range of pharmaceutical products and healthcare services aimed at veterinary care. Its core offerings include prescription medications, over-the-counter drugs, and health supplements designed to address various medical conditions in animals. The company targets retail pharmacies, healthcare professionals, and direct consumers who require effective treatment solutions for animal health. It serves markets across East Asia, Southeast Asia, and select regions in North America, ensuring a broad reach for reliable veterinary pharmaceutical options. Revenue generation for 12 Pharmacy is primarily through direct sales to pharmacies and healthcare providers, as well as online distribution channels. The company engages in bulk purchasing agreements with retailers to maintain a steady flow of products. Partnerships with healthcare institutions promote its flagship products, which are often sold through subscription models for ongoing veterinary care. Pricing strategies include competitive rates for individual units and discounts for larger orders, supporting a sustainable business model that encompasses both B2B and direct-to-consumer markets.

The company will use the April 2026 funding to expand its online prescription and pharmaceutical services for animal hospitals and reduce the operational burden on veterinary professionals.

## Funding rounds

- Series A, Apr 20, 2026 — FFG Venture Business Partners, Beta Venture Capital, ARKRAY&PARTNERS Pte. Ltd.
- Series A, Jan 14, 2026 — Global Brain, Shizuoka Capital, pipon

## Investors

- Global Brain (https://capitalatlas.ai/funds/global-brain) — Series A
- Shizuoka Capital (https://capitalatlas.ai/funds/shizuoka-capital) — Series A
- pipon — Series A
- FFG Venture Business Partners (https://capitalatlas.ai/funds/ffg-venture-business-partners) — Series A
- Beta Venture Capital (https://capitalatlas.ai/funds/beta-venture-capital) — Series A
- ARKRAY&PARTNERS Pte. Ltd. — Series A